DSP-0038

**DSP-0038** is an oral small molecule antipsychotic discovered by Sumitomo Pharma in collaboration with Recursion (formerly Exscientia) using AI-driven drug design. It acts as a **serotonin 5-HT2A receptor antagonist** and **serotonin 5-HT1A receptor agonist**, leveraging their additive effects for enhanced antipsychotic efficacy while exhibiting negligible affinity for dopamine D2 receptors, potentially improving safety and tolerability over existing antipsychotics. It is being developed primarily for **psychosis in Alzheimer's disease** and shows promise for broader **behavioral and psychological symptoms of dementia (BPSD)**, including agitation, aggression, anxiety, and depression.[1][2][3][5]